Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Peregrine Pharmaceuticals (NASDAQ:PPHM), NOW Inc (NYSE:DNOW), Wayfair Inc (NYSE:W), Achillion Pharmaceuticals, Inc (NASDAQ:ACHN)

Their insights are depicted underneath:

Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares picked up 3.82%, and closed at $1.57.

According to GLOBE NEWSWIRE, Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical corporation focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, recently declared that it will report financial results for the third quarter fiscal year (FY) 2015 ended January 31, 2015 on March 12, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine’s senior administration will talk about financial results for the third quarter ended January 31, 2015 of FY 2015 and will review recent progress of its clinical development programs.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical corporation with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The corporation’s lead immuno-oncology candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the “SUNRISE trial”) together with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.

NOW Inc (NYSE:DNOW), raised 3.78%, and closed at $23.62.

According to BUSINESS WIRE, on February 23, NOW Inc. (DNOW), stated that for its fourth quarter ended December 31, 2014 it earned net revenue of $16 million, or $0.14 per fully diluted share. Proceed stated for the full year 2014 was $4,105 million, and net revenue was $116 million, or $1.06 per fully diluted share.

Proceed for the fourth quarter reduced 6.0 percent sequentially to $1,006 million. Earnings before interest, taxes, depreciation and amortization for the fourth quarter of 2014 was $31 million or 3.1% of sales.

Robert Workman, President and CEO of NOW Inc., commented, “2014 marked an adventurous year for DistributionNOW. The year started with excitement from our spin-off from National Oilwell Varco and the creation of our own stand-alone publicly traded corporation. Simultaneously, we implemented a new ERP system and integrated three very large distribution businesses. While these efforts consumed more resources and time than anticipated, we believe that much of that work is behind us now. Despite that noise, and the more recent bearish sentiment in the market, our employees have remained resilient and I couldn’t be more proud. We have accomplished a lot over the past twelve months, and I am looking forward to using that experience into the new year.

NOW Inc. is one of the largest distributors to energy and industrial markets on a worldwide basis, with a legacy of over 150 years. NOW Inc. operates primarily under the DistributionNOW and Wilson Export brands. Through its network of over 300 locations and about 5,000 employees worldwide, NOW Inc. offers a comprehensive line of products and solutions for the upstream, midstream and downstream energy and industrial sectors.

Wayfair Inc (NYSE:W), enhanced 3.71%, and closed at $28.81.

According to BUSINESS WIRE, Wayfair Inc. (W), one of the world’s largest online destinations for home furnishings and décor, stated financial results for its fourth quarter and full fiscal year ended December 31, 2014.

Fourth Quarter 2014 Financial Highlights:

• Net proceed raised to $408.6 million, up 38.4% year over year
• Direct Retail proceed, comprising of sales generated primarily through the sites of Wayfair’s five brands, raised to $346.7 million, up 55.2 % year over year
• Gross profit was $98.4 million or 24.1% of proceed, contrast to 23.9% of proceed in the same quarter last year
• Adjusted EBITDA was $(7.2) million
• GAAP basic and diluted net loss per share was $0.73
• Non GAAP diluted net loss per share was $0.18
• Non GAAP free cash flow was $50.8 million
• At the end of the Fourth Quarter, cash, cash equivalents, and short-term investments totaled $415.9 million.

Full Year 2014 Financial Highlights:

• Net proceed raised to $1.3 billion, up 44.0% year over year
• Direct Retail proceed raised to $1.1 billion, up 63.6% year over year
• Adjusted EBITDA was $(62.5) million
• Non GAAP diluted net loss per share was $1.02 for the year
• Non GAAP free cash flow for the year was $(41.9) million.

Wayfair Inc. engages in the e-commerce business in the United States. The corporation primarily offers furniture, décor, lighting, kitchen, bed and bath, outdoor, home improvement, and baby and kids products under the Wayfair.com, Joss & Main, AllModern, DwellStudio, and Birch Lane brands. It also sells its products through retail partners. The corporation was founded in 2002 and is headquartered in Boston, Massachusetts.

Achillion Pharmaceuticals, Inc (NASDAQ:ACHN), enhanced 3.64%, and closed at $11.39.

According to GLOBE NEWSWIRE, Achillion Pharmaceuticals, Inc. (ACHN), stated financial results for the three and twelve months ended December 31, 2014.

For the three months ended December 31, 2014, the Corporation stated a net loss of $21.6 million, contrast to a net loss of $13.4 million in the three months ended December 31, 2013. For the full year ended December 31, 2014, the Corporation’s net loss was $69.0 million, or $0.70 per share, contrast to a net loss of $58.9 million for the year ended December 31, 2013, or $0.63 per share. Cash, cash equivalents, marketable securities, and interest and subscriptions receivable at December 31, 2014 were $159.2 million.

Anticipated Milestones for 2015:

Sparta Doublet Regimen for HCV:

• Plan to initiate in the first half of 2015 a clinical trial with ACH-3422 in combination with ACH-3102 for patients with treatment-naive genotype 1 HCV for treatment durations of 6, 8 and 12 weeks. SVR4 results are predictable in the second half of 2015.

ACH-3422 Phase 1 Proof-of-concept for HCV Genotypes 2 and 3:

• Plan to initiate during the first quarter a Phase 1 proof-of-concept trial evaluating the anti-viral activity of ACH-3422 for HCV genotypes 2 and 3. Results are anticipated during the second quarter of 2015.

Ithaca Triplet Regimen for HCV:

• Expect to initiate during the first half of 2015 a proxy triplet trial evaluating ACH-3102 and sovaprevir with sofosbuvir for a treatment duration of 4 weeks. SVR4 results are predictable in the second half of 2015; and
• Expect to initiate by the end of 2015 a pharmacokinetic and viral kinetic study of ACH-3422, ACH-3102 and sovaprevir in patients with treatment-naive genotype 1 HCV.

Complement Factor D Inhibitor Program:

• Expect to nominate a novel orally-administered complement factor D inhibitor and advance into a phase I clinical trial by the end of 2015.

Achillion is seeking to apply its expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving patients’ lives.